Metrics For Measuring UK Pricing Scheme Success: Good Start But More Work Needed
Executive Summary
The Pink Sheet’s freedom of information request relating to the 2019 pricing and access to branded medicines scheme has shed light on the metrics being used to gauge whether the scheme is delivering on its promise.
You may also be interested in...
Concerns Emerge Over England’s Desire For Even Lower Drug Prices
With the emphasis on getting lower prices even for cost-effective drugs, England’s proposed commercial framework may be sending a negative signal to global companies.
£197m Payments Made Under New UK Pricing Scheme But Access Promises Still To Materialize
Payments have now been made under the UK’s 2019 pricing and access to branded medicines scheme, but industry will have to wait longer for promises on access to materialize.
We Need To Talk – When To Get Early Scientific Advice
Hearing direct from HTA agencies on what evidence they want to see is now an option through early dialogue. With many options for early dialogue available, it is hard for companies to know whether to get advice, from which agency and how to get the most out of the dialogue.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: